Frequency Therapeutics, Inc. (FREQ)
| Previous Close | 0.4500 |
| Open | 0.4500 |
| Bid | 0.4520 x 2900 |
| Ask | 0.4693 x 1000 |
| Day's Range | 0.4310 - 0.4750 |
| 52 Week Range | 0.4310 - 5.5900 |
| Volume | |
| Avg. Volume | 859,020 |
| Market Cap | 16.37M |
| Beta (5Y Monthly) | 0.69 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results
LEXINGTON, Mass., March 10, 2023--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2022.
- Business Wire
Frequency Therapeutics to Participate at Upcoming March Investor Conferences
LEXINGTON, Mass., February 27, 2023--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced that interim Chief Executive Officer and Chief Scientific Officer Christopher Loose, Ph.D., will present at the following March healthcare investor conferences:
- Business Wire
Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss
LEXINGTON, Mass., February 13, 2023--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a regenerative medicine company focused on developing therapeutics to activate a person’s innate potential to restore function, today announced clinical results from the placebo-controlled Phase 2b study of FX-322 in individuals with acquired Sensorineural Hearing Loss (SNHL).
